MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Cancer research · 2003

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo Frank, Discafani Carolyn M, Annable Tami, Beyer Carl, Musto Sylvia, Hari Malathi, Tan Xingzhi, Hardy Carolyn, Hernandez Richard, Baxter Michelle, Singanallore Thiruvikraman, Khafizova Gulnaz, Poruchynsky Marianne S, Fojo Tito, Nieman James A, Ayral-Kaloustian Semiramis, Zask Arie, Andersen Raymond J, Greenberger Lee M

СтатьяПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

Hemiasterlin is a natural product derived from marine sponges that, like other structurally diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules. Total synthesis of hemiasterlin and its analogues has been accomplished, and optimal pharmacological features of the series have been explored. The biological profile of one analogue, HTI-286, was studied here. HTI-286 inhibited the polymerization of purified tubulin, disrupted microtubule organization in cells, and induced mitotic arrest, as well as apoptosis. HTI-286 was a potent inhibitor of proliferation (mean IC(50) = 2.5 +/- 2.1 nM in 18 human tumor cell lines) and had substantially less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule agents, including paclitaxel, docetaxel, vinorelbine, or vinblastine. Resistance to HTI-286 was not detected in cells overexpressing the drug transporters MRP1 or MXR. In athymic mice implanted with human tumor xenografts, HTI-286 administered i.v. in saline inhibited the growth of numerous human tumors derived from carcinoma of the skin, breast, prostate, brain, and colon. Marked tumor regression was observed when used on established tumors that were >1 gram in size. Moreover, HTI-286 inhibited the growth of human tumor xenografts (e.g., HCT-15, DLD-1, MX-1W, and KB-8-5) where paclitaxel and vincristine were ineffective because of inherent or acquired resistance associated with P-glycoprotein. Efficacy was also achieved with p.o. administration of HTI-286. These data suggest that HTI-286 has excellent preclinical properties that may translate into superior clinical activity, as well as provide a useful synthetic reagent to probe the drug contact sites of peptide-like molecules that interact with tubulin.

Для цитирования: Loganzo Frank, Discafani Carolyn M, Annable Tami, Beyer Carl, Musto Sylvia, Hari Malathi, Tan Xingzhi, Hardy Carolyn, Hernandez Richard, Baxter Michelle, Singanallore Thiruvikraman, Khafizova Gulnaz, Poruchynsky Marianne S, Fojo Tito, Nieman James A, Ayral-Kaloustian Semiramis, Zask Arie, Andersen Raymond J, Greenberger Lee M. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.. Cancer research. 2003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.